Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Spektrum der Augenheilkunde
Erschienen in:

01.10.2012 | original article

Limited vitrectomy with intravitreal bevacizumab, rt-PA and gas for submacular hemorrhage due to age-related macular degeneration

verfasst von: Dr. Lisa Tarmann, MD, Andreas Wedrich, Anton Haas, MD, Andrea Berghold, PhD, Adelheid Kresse, PhD, Christian Vajda, Richard Maier, MD

Erschienen in: Spektrum der Augenheilkunde | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Summary

Purpose

To investigate the safety and efficacy of limited vitrectomy with intravitreal bevacizumab, recombinant tissue plasminogen activator (rt-PA) and gas for displacement of submacular hemorrhage due to exudative age-related macular degeneration (AMD).

Methods

In this retrospective pilot study 11 eyes of 11 patients with submacular hemorrhage secondary to AMD were analyzed.
A limited 23 g-one-port pars plana vitrectomy was performed and 50 μg rt-PA, 1.25 mg bevacizumab and about 1.5 mL of 100 % sulfur hexafluoride (SF6) were injected into the vitreous. The best and the final visual acuity and blood displacement from the fovea were evaluated postoperatively.

Results

The best postoperative visual acuity (VA) was obtained at a median of 1 month after surgery (range 0.5–6 months) and demonstrated significantly better results than baseline VA for a short period of time (p = 0.04). No statistically significant improvement (p = 0.11) of the final visual acuity at a median of 3 months (range 0.5–6 months) compared to preoperative was found. Final visual acuity improved in 7 eyes, remained stable in 2 eyes and worsened in 2 eyes. Total pneumatic displacement of the submacular hemorrhage was obtained in 5 (46 %) eyes, partial displacement was shown in 2 (18 %) eyes. There was no displacement of the subretinal hemorrhage in 4 (36 %) eyes.

Conclusion

This surgical procedure seems to have no advantage over intravitreous injection of rt-PA and gas with or without complete vitrectomy concerning displacement rate of submacular hemorrhage and postoperative visual acuity.
Vorheriger Artikel Pharmakologische Basis der Anti-VEGF Therapie
Nächster Artikel Risikofaktoren retinaler Arterienverschlüsse
Literatur
1.
Avery RL, Fekrat S, Hawkins BS, et al. Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina. 1996;16(3):183–9.PubMedCrossRef
2.
Toth CA, Morse LS, Hjelmeland LM, et al. Fibrin directs early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol. 1991;109(5):723–9.PubMedCrossRef
3.
Gillies A, Lahav M. Absorption of retinal and subretinal hemorrhages. Ann Ophthalmol. 1983;15(11):1068–74.PubMed
4.
Scupola A, Coscas G, Soubrane G, et al. Natural history of macular subretinal hemorrhage in age-related macular degeneration. Ophthalmologica. 1999;213(2):97–102.PubMedCrossRef
5.
Bennett SR, Folk JC, Blodi CF, et al. Factors prognostic of visual outcome in patients with subretinal hemorrhage. Am J Ophthalmol. 1990;109(1):33–7.PubMed
6.
Guthoff R, Guthoff T, Meigen T, et al. Intravitreous injection of bevacizumab, tissue plasminogen activator, and gas in the treatment of submacular hemorrhage in age-related macular degeneration. Retina. 2011;31(1):36–40.
7.
Krepler K, Kruger A, Tittl M, et al. Intravitreal injection of tissue plasminogen activator and gas in subretinal hemorrhage caused by age-related macular degeneration. Retina. 2000;20(3):251–6.PubMedCrossRef
8.
Oshima Y, Ohji M, Tano Y. Pars plana vitrectomy with peripheral retinotomy after injection of preoperative intravitreal tissue plasminogen activator: a modified procedure to drain massive subretinal haemorrhage. Br J Ophthalmol. 2007;91(2):193–8.PubMedCrossRef
9.
Hillenkamp J, Surguch V, Framme C, et al. Management of submacular hemorrhage with intravitreal versus subretinal injection of recombinant tissue plasminogen activator. Graefes Arch Clin Exp Ophthalmol. 2010;248(1):5–11.PubMedCrossRef
10.
Hassan AS, Johnson MW, Schneiderman TE, et al. Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement. Ophthalmology. 1999;106(10):1900–6; discussion 1906–7.PubMedCrossRef
11.
Hesse L, Kroll P. Successful treatment of acute subretinal hemorrhage in age-related macular degeneration by combined intravitreal injection of recombinant tissue plasminogen activator and gas. Adv Ther. 1997;14(5):275–80.PubMed
12.
13.
Fujii GY, De Juan E Jr, Humayun MS, et al. Initial experience using the transconjunctival sutureless vitrectomy system for vitreoretinal surgery. Ophthalmology. 2002;109(10):1814–20.PubMedCrossRef
14.
Haas A, Seidel G, Steinbrugger I, Maier R, Gasser-Steiner V, Wedrich A, Weger M. Twenty-three-gauge and 20-gauge vitrectomy in epiretinal membrane surgery. Retina. 2010; 30(1):112–6.PubMedCrossRef
15.
Lange C, Feltgen N, Junker B, et al. Resolving the clinical acuity categories “hand motion” and “counting fingers” using the Freiburg Visual Acuity Test (FrACT). Graefes Arch Clin Exp Ophthalmol. 2009;247(1):137–42.PubMedCrossRef
16.
Schulze SD, Hesse L. Tissue plasminogen activator plus gas injection in patients with subretinal hemorrhage caused by age-related macular degeneration: predictive variables for visual outcome. Graefes Arch Clin Exp Ophthalmol. 2002;240(9):717–20.PubMedCrossRef
17.
Mozaffarieh M, Heinzl H, Sacu S, et al. In-patient management and treatment satisfaction after intravitreous plasminogen activator injection. Graefes Arch Clin Exp Ophthalmol. 2006;244(11):1421–8.PubMedCrossRef
18.
Hesse L, Schmidt J, Kroll P. Management of acute submacular hemorrhage using recombinant tissue plasminogen activator and gas. Graefes Arch Clin Exp Ophthalmol. 1999;237(4):273–7.PubMedCrossRef
19.
Handwerger BA, Blodi BA, Chandra SR, et al. Treatment of submacular hemorrhage with low-dose intravitreal tissue plasminogen activator injection and pneumatic displacement. Arch Ophthalmol. 2001;119(1):28–32.PubMed
20.
Hattenbach LO, Klais C, Koch FH, et al. Intravitreous injection of tissue plasminogen activator and gas in the treatment of submacular hemorrhage under various conditions. Ophthalmology. 2001;108(8):1485–92.PubMedCrossRef
21.
Meyer CH, Scholl HP, Eter N, et al. Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: a retrospective pilot study. Acta Ophthalmol. 2008;86(5):490–4.PubMedCrossRef
22.
Arias L, Mones J. Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration. Clin Ophthalmol. 2010;4:67–72.PubMedCrossRef
23.
Auriol S, Mahieu L, Lequeux L, et al. Pars plana vitrectomy, subretinal injection of recombinant tissue plasminogen activator and fluid-gas exchange in the management of massive submacular hemorrhages secondary to age-related macular degeneration. J Fr Ophtalmol. 2010;33(2):84–91.PubMedCrossRef
24.
Haupert CL, McCuen BW 2nd, Jaffe GJ, et al. Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration. Am J Ophthalmol. 2001;131(2):208–15.PubMedCrossRef
25.
Singh RP, Patel C, Sears JE. Management of subretinal macular haemorrhage by direct administration of tissue plasminogen activator. Br J Ophthalmol. 2006;90(4):429–31.PubMedCrossRef
26.
Treumer F, Klatt C, Roider J, et al. Subretinal coapplication of recombinant tissue plasminogen activator and bevacizumab for neovascular age-related macular degeneration with submacular haemorrhage. Br J Ophthalmol. 2010;94(1):48–53.PubMedCrossRef
27.
Olivier S, Chow DR, Packo KH, et al. Subretinal recombinant tissue plasminogen activator injection and pneumatic displacement of thick submacular hemorrhage in Age-Related macular degeneration. Ophthalmology. 2004;111(6):1201–8.PubMedCrossRef
28.
Krebs I, Brannath W, Glittenberg C, et al. Posterior vitreomacular adhesion: a potential risk factor for exudative age-related macular degeneration? Am J Ophthalmol. 2007;144(5):741–6.
29.
Verma D, Jalabi MW, Watts WG, et al. Evaluation of posturing in macular hole surgery. Eye (Lond). 2002;16(6):701–4.CrossRef
30.
Lincoff H, Kreissig I, Stopa M, et al. A 40 degrees gaze down position for pneumatic displacement of submacular hemorrhage: clinical application and results. Retina. 2008;28(1):56–9.PubMedCrossRef
31.
Stopa M, Lincoff A, Lincoff H. Analysis of forces acting upon submacular hemorrhage in pneumatic displacement. Retina. 2007;27(3):370–4.PubMedCrossRef
Metadaten
Titel
Limited vitrectomy with intravitreal bevacizumab, rt-PA and gas for submacular hemorrhage due to age-related macular degeneration
verfasst von
Dr. Lisa Tarmann, MD
Andreas Wedrich
Anton Haas, MD
Andrea Berghold, PhD
Adelheid Kresse, PhD
Christian Vajda
Richard Maier, MD
Publikationsdatum
01.10.2012
Verlag
Springer Vienna
Erschienen in
Spektrum der Augenheilkunde / Ausgabe 4/2012
Print ISSN: 0930-4282
Elektronische ISSN: 1613-7523
DOI
https://doi.org/10.1007/s00717-012-0119-4

Weitere Artikel der Ausgabe 4/2012

Selektive Lasertrabekuloplastik bei Patienten unter maximaler Lokaltherapie: eine retrospektive Analyse

  • originalarbeit

Univ. Prof. Dr. Karlheinz Schenk 1925–2012

  • berichte und interviews

Editorial

  • editorial

Entwicklung und Implementierung eines Leitbildes an der Universitäts-Augenklinik Graz

  • originalarbeit

Risikofaktoren retinaler Arterienverschlüsse

  • originalarbeit

Hat sich das Altersprofil der Kataraktpatienten in den letzten 14 Jahren geändert? Eine Analyse von 76.760 Phakoemulsifikationen

  • originalarbeit